Condition
Advanced/Metastatic Breast Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownMegestrol Acetate for Fatigue Management in T-DXd Treated Breast CancerNCT07543536 · 2026-06-08
RECRUITINGDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerNCT07610720 · 2026-06-01
RECRUITINGPraegnant Breast Cancer: Early/Advanced/MetastaticNCT02338167 · 2014-06-01
RECRUITINGStudy Of Sunitinib With Capecitabine In Breast CancerNCT00662025 · 2008-04-01
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
RECRUITING3
COMPLETED1
Phase mix
PHASE22
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.